Journal
FRONTIERS IN ENDOCRINOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2021.624686
Keywords
non-surgical therapy; Temozolomide; CAPTEM; PRRT (Peptide Receptor Radionuclide Therapy); aggressive pituitary tumors; pituitary carcinomas
Categories
Funding
- Graduate School, University of Minnesota [UMF0011528]
- University of Alberta
- University Hospital Foundation
- US National Institutes of Health [AR064195]
Ask authors/readers for more resources
Up to 35% of aggressive pituitary tumors recur and current treatment options often fail to inhibit tumor growth. Chemotherapeutic drugs and peptide receptor radionuclide therapy are being increasingly researched for their potential anti-tumor effects on aggressive pituitary tumors.
Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of life. Management can be challenging and often requires multimodal treatment. Current treatment options, including surgery, conventional medical therapies such as dopamine agonists, somatostatin receptor agonists and radiotherapy, often fail to inhibit pituitary tumor growth. Recently, anti-tumor effects of chemotherapeutic drugs such as Temozolomide, Capecitabine, and Everolimus, as well as peptide receptor radionuclide therapy on aggressive pituitary tumors have been increasingly investigated and yield mixed, although sometimes promising, outcomes. The purpose of this review is to provide thorough information on non-surgical medical therapies and their efficacies and used protocols for aggressive pituitary adenomas from pre-clinical level to clinical use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available